27Jul 2024
Sun Pharma's New Baldness Drug Approved by US FDA

Sun Pharma's New Baldness Drug Approved by US FDA

Sun Pharma's baldness treatment, Leqselvi (deuruxolitinib), has received US FDA approval for severe alopecia areata. Acquired through the $576 million purchase of Concert Pharmaceuticals in January 2023, the drug is a potential game-changer in alopecia treatment. Deuruxolitinib, a JAK inhibitor, offers new hope for patients and will be marketed exclusively by Sun Pharma for five years. Shares surged following the announcement.

  • #general surgery
  • #pharmacology
  • #general medicine
  • #psych
  • #rheumatology
  • #pathology
  • #radiology
  • #anaesthesia
  • #psychiatry
  • #fmt
  • #emergency medicine
  • #academics
  • #nursing
  • #pharmacy
  • #trichology
  • #andrology
  • #orthopaedics
  • #critical care
  • #dermatology
  • #dentistry
  • #oncology
  • #business
  • #gastroenterology
  • #nephrology
  • #diagnostics
  • #urology
  • #ophthalmology
  • #gynaecology - ivf
  • #pediatrics
  • #neurology
  • #ent
  • #pulmonology
  • #family health
  • #cardiology
  • #endo-diabetology

Like

Save

Share